HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody. The phase 1 clinical trial in China is a multicenter, open-label study, which will assess HMPL-A83’s safety, tolerability, pharmacokinetics, and preliminary efficacy in […]